Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gefapixant: First Approval.

Drugs·2022
Same author

Daridorexant: First Approval.

Drugs·2022
Same author

Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.

Targeted oncology·2022
Same author

Envafolimab: First Approval.

Drugs·2022
Same author

Tisotumab Vedotin: First Approval.

Drugs·2021
Same author

Mobocertinib: First Approval.

Drugs·2021
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Oct 27, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.2K

Pamiparib: First Approval.

Anthony Markham1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|July 21, 2021
PubMed
Summary
This summary is machine-generated.

Pamiparib, a PARP1/2 inhibitor, is approved in China for recurrent ovarian, fallopian tube, and peritoneal cancers with BRCA mutations. This marks a significant milestone for this targeted cancer therapy.

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K
Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs
11:00

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Published on: June 12, 2018

14.1K

Related Experiment Videos

Last Updated: Oct 27, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.2K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K
Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs
11:00

Biotin-based Pulldown Assay to Validate mRNA Targets of Cellular miRNAs

Published on: June 12, 2018

14.1K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Pamiparib is a selective inhibitor of poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2).
  • PARP inhibitors are a class of targeted cancer therapies.
  • Development of novel cancer treatments is ongoing.

Purpose of the Study:

  • To summarize the development of pamiparib.
  • To highlight the milestones leading to its first approval.

Main Methods:

  • Review of pivotal phase II trial data (NCT03333915).
  • Analysis of clinical development pathway for pamiparib.

Main Results:

  • Pamiparib demonstrated efficacy in a phase I/II trial.
  • The drug received approval in China.

Conclusions:

  • Pamiparib is approved for specific gynecological cancers with BRCA mutations.
  • This approval represents a key advancement in the treatment of these cancers.